Ruxolitinib

Generic Name: Ruxolitinib

Brand Names: Jakafi, Jakavi, Opzelura

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈N_₆

CAS Number: 941678-49-5

Unique Ingredient Identifier: 82S8X8XX8H

Background: Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...

Indication: Ruxolitinib is indicated for the treatment of the following conditions:

Topical ruxolitinib is indicated for:

Associated Conditions: Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera

Associated Therapies: -

Clinical Trials

Study of Ruxolitinib in Colorectal Cancer Patients

Phase 2

Terminated

Conditions: CRC (Colorectal Cancer)

Interventions: Drug: Ruxolitinib
Drug: Regorafenib
Drug: Placebo

First Posted Date: 2014-04-22

Last Posted Date: 2018-02-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 396

Registration Number: NCT02119676

A Study of Ruxolitinib in Pancreatic Cancer Patients

Phase 3

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Placebo
Drug: Ruxolitinib
Drug: Capecitabine

First Posted Date: 2014-04-22

Last Posted Date: 2018-02-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 86

Registration Number: NCT02119663

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Ruxolitinib
Drug: Capecitabine
Drug: Placebo

First Posted Date: 2014-04-22

Last Posted Date: 2018-02-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 149

Registration Number: NCT02120417

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Phase 2

Terminated

Conditions: NSCLC (Non-small Cell Lung Carcinoma)

Interventions: Drug: Placebo
Drug: Ruxolitinib
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2014-04-22

Last Posted Date: 2018-02-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 76

Registration Number: NCT02119650

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Phase 3

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Placebo
Drug: Ruxolitinib
Drug: Capecitabine

First Posted Date: 2014-04-21

Last Posted Date: 2019-03-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 321

Registration Number: NCT02117479

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Phase 2

Terminated

Conditions: Primary Myelofibrosis

Interventions: Drug: Ruxolitinib

First Posted Date: 2014-03-19

Last Posted Date: 2016-03-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT02091752

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Phase 3

Completed

Conditions: Primary Myelofibrosis (MF)

Interventions: Drug: Ruxolitinib

First Posted Date: 2014-03-14

Last Posted Date: 2016-07-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT02087059

Locations: 🇯🇵
Novartis Investigative Site, Gifu, Japan

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Phase 1

Completed

Conditions: Myeloproliferative Neoplasms

Interventions: Drug: Ruxolitinib
Drug: Decitabine

First Posted Date: 2014-03-03

Last Posted Date: 2019-02-28

Lead Sponsor: John Mascarenhas

Target Recruit Count: 49

Registration Number: NCT02076191

Locations: 🇺🇸
Washington University of St. Louis, Saint Louis, Missouri, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 5 locations

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Phase 2

Terminated

Conditions: Cancer Cachexia

Interventions: Drug: Ruxolitinib

First Posted Date: 2014-02-26

Last Posted Date: 2019-02-28

Lead Sponsor: Kantonsspital Aarau

Target Recruit Count: 8

Registration Number: NCT02072057

Locations: 🇨🇭
Division of Hematology/Oncology, Kantonsspital Olten, Olten, SO, Switzerland
🇨🇭
Division of Hematology/Oncolgy, University Clinic of Medicine, Kantonsspital Aarau AG, Aarau, AG, Switzerland

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer
HER-2 Positive Breast Cancer
Breast Carcinoma

Interventions: Drug: Ruxolitinib
Drug: Trastuzumab

First Posted Date: 2014-02-19

Last Posted Date: 2023-08-24

Lead Sponsor: Dawn L. Hershman

Target Recruit Count: 32

Registration Number: NCT02066532

Locations: 🇺🇸
New York Hospital-Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy